Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of AR046917A1publicationCriticalpatent/AR046917A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente se refiere a ciertos péptidos y péptidos conjugados biologicamente activos que se pueden utilizar en medidas terapéuticas y profilácticas contra enfermedades o cuadros relacionados con B1 como agente causativo. En una forma de realizacion preferida, se proporcionan péptidos conjugados con PEG biologicamente activos. En un aspecto de la presente, los péptidos conjugados con PEG farmacologicamente activos resultan de utilidad para tratar la inflamacion o el dolor.This refers to certain biologically active conjugated peptides and peptides that can be used in therapeutic and prophylactic measures against diseases or conditions related to B1 as the causative agent. In a preferred embodiment, biologically active PEG conjugated peptides are provided. In one aspect of the present, pharmacologically active PEG conjugated peptides are useful for treating inflammation or pain.
ARP0401038342003-10-222004-10-22
A COMPOSITION THAT INCLUDES ANTAGONISTS OF THE BRADICININE B1 RECEIVER
AR046917A1
(en)
Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
Oral care composition comprising an effective amount of a basic amino acid and an antibacterial agent; use in the antibacterial treatment of the oral cavity.
Heterocyclic derived compounds, cb2 modulators; pharmaceutical composition comprising them; and use in the treatment of rheumatic, autoimmune, inflammatory diseases, pain, among others.
Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain